← Eichor
Study identifier: NCT05874154 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of Tibial Nerve Selective Neurotomy Compared to Botulinum Toxin Injections for Spastic Foot Treatment in Post-stroke Patients According to a Goal-centered Approach

Condition: Post Stroke Seizure · Spastic Foot  ·  Sponsor: Hospices Civils de Lyon

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

In France, more than 110.000 patients are hospitalized for stroke per year. It is the leading cause of sudden disabilities in adults. Incidence of spastic foot is evaluated at 1 year post stroke from 18% to 56% of hemiplegic patients. Spasticity, defined as an increase in the velocity-dependent response to muscle stretch measured at rest, is part of the upper motor neuron syndrome and is characterized by an increase in tonic stretch reflex. It has been proposed that upper motor neuro syndrome may induce not only spasticity but also other types of muscles overactivity such as spastic dystonia, co-contraction and clonus. In hemiplegic patients, lower limb spasticity within the posterior part of the leg frequently results in equino-varus foot and toes claw. These abnormal postures in hemiplegics may affect activities of daily living such as shoes fitting, balance, ambulation-walking, comfort (pain) and may become irreducible (tendon shortening) if not treated. The purpose of this study is to compare the interest of each treatment (BoNT-A versus STN) in order to specify both techniques indications and up-date current guidelines of lower-limb spasticity for hemiplegic patients. This study aims to confirm a greater reduction of calf muscles spasticity after STN as compared to BoNT-A, as observed in the only published monocentric randomized controlled trial. Our study originality is to perform a multi-center RCT with a pre-established sample size. This study will also quantify pro…

This description comes directly from the study's public registry record.

Talk to the study team

Jacques LUAUTE, MD,PhD  ·  04 72 35 71 69  ·  jacques.luaute@chu-lyon.fr

Anne-Laure CHARLOIS  ·  0472355837  ·  anne-laure.charlois@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (4)

Hôpital Pierre WertheimerBron, FranceNot Yet Recruiting
AP-HPClichy, FranceNot Yet Recruiting
CHU de NantesNantes, FranceNot Yet Recruiting
Hôpital Henry GabrielleSaint-Genis-Laval, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05874154